Generic Name and Formulations:
Patiromer 8.4g, 16.8g, 25.2g; per pkt; pwd for oral susp.
Indications for VELTASSA:
Limitations Of use:
Not for emergency treatment for life-threatening hyperkalemia due to its delayed onset of action.
Give at least 3hrs before or 3hrs after other oral medications. Take without regard to food; mix with water. Initially 8.4g once daily. Adjust dose in 8.4g increments as needed at ≥1-week intervals to obtain desired serum potassium target range; max 25.2g/day.
Binding to other oral medications.
Avoid in severe constipation, bowel obstruction or impaction, abnormal post-op bowel motility disorders. Monitor serum potassium, magnesium. Consider magnesium supplementation if low serum levels develop.
May reduce absorption and efficacy of other oral medications; separate dosing by at least 3hrs.
Constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort, flatulence.
Single-use packets (8.4g)—4, 30; (16.8g, 25.2g)—30
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC